Multiple Dose Escalation Study of M201-A in Healthy Japanese Subjects

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

18 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-03-30

Study Completion Date

2020-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This Phase I is designed to evaluate the safety, tolerability and pharmacokinetics of multiple ascending doses of M201-A administered by multiple continuous intravenous injection in Healthy Japanese subjects.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

First-in-Human Dose Escalation Study of M201-A in Healthy Japanese Subjects

NCT03055403

Healthy Volunteers

COMPLETED PHASE1

AZD2624 Multiple Ascending Dose Study in Japan

NCT00696865

Healthy Safety

COMPLETED PHASE1

A Study to Assess the Safety and Tolerability of E6742 in Japanese Healthy Adult Participants

NCT04683185

Healthy Volunteers

COMPLETED PHASE1

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 in Healthy Japanese Male Volunteers

NCT00421226

Healthy

COMPLETED PHASE1

Multiple Ascending Dose Study for AZD 7268 in Japanese Healthy Male Volunteers

NCT01116011

Healthy

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Volunteers

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

M201-A Injection

Active Substance: M201-A Route of administration: continuous intravenous injection

Group Type EXPERIMENTAL

M201-A Injection

Intervention Type DRUG

Active Substance: M201-A Route of administration: continuous intravenous injection

Placebo

Placebo: M201-A Placebo Route of administration: continuous intravenous injection

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo: M201-A Placebo Route of administration: continuous intravenous injection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

M201-A Injection

Active Substance: M201-A Route of administration: continuous intravenous injection

Intervention Type DRUG

Placebo

Placebo: M201-A Placebo Route of administration: continuous intravenous injection

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Subjects must satisfy the following criteria to be enrolled in the study

* (1)Japanese Healthy Male subjects
* (2)Age 20 to less than 50 years of age
* (3)Body Weight of more than 50 kg, Body Mass Index (BMI) of 18.5 to less than 25.0 kg/m2 at the screening examination
* (4)Written informed consent must be obtained on a voluntary basis before any assessment is performed.

Exclusion Criteria

The presence of any of the following will exclude a subject from enrollment:

* (1)Presence or past medical history of hepatic impairments, renal impairments, cardiovascular disease, gastrointestinal disease and others which are inappropriate for participating in this clinical trial
* (2)Past medical history of cancer, cerebral infarction or cardiac infarction
* (3)Past history of surgical operation of gastrointestine or kidney except appendectomy or hemorrhoid operation.
* (4)Presence or past history of epilepsy.
* (5)Presence or past medical history of allergic reactions or idiosyncrasies to food, medicinal substance and metallic materials
* (6)heart rate(HR) \>= 100 bpm at the screening examination
* (7)The corrected QT interval(QTcF) \>= 440 ms at the screening examination
* (8)brain natriuretic peptide(BNP) \> 40 pg/mL at the screening examination
* (9)K\<3.6 mEq/L at the screening examination
* (10)Past history or suspect of aldosteronism.
* (11)Any risk factors of Torsades de Pointes including such as heart failure, hypokalemia, long QT interval syndrome due to family medical history
* (12)Cre\>1.10 mg/dL, \<0.85 mg/dL at the screening examination
* (13)Subject who donated whole blood of 400 mL within 12 weeks or whole blood of 400 mL of 200 mL / blood component donation within 4weeks prior to the first administration.
* (14)Use of prescription drug, over-the-counter medications (except eye drops for dryness, sanitizer for preventing infection), or herbal medication within 4 weeks prior to study medication.
* (15)Subject who consumed furanocoumarin containing food within 7 days prior to study medication.
* (16)Subject who drunk alcohol or caffeine containing drink within 3 days prior to study medication.
* (17)Subject who was administered of another investigational drug within16 weeks prior to agree to participate in this study.
* (18)Subject who was administered M201-A in the past.
* (19)Subject who smoke within 90 day prior to study medication or who cannot quit smoking during the study period.
* (20)Subject with positive result in hepatitis B(HB)s antigen, hepatitis C virus(HCV) antibody, HIV antigen/antibody, Syphilis serum, urine drug test at the screening test. Subject with positive result in Coronavirus(COVID-19) test at the screening or at the hospitalization.
* (21) Presence or past history of drug/alcohol abuse.
* (22)Subject who do not use medically acceptable contraceptive method until 90 days after the final study drug administration.
* (23)Subject who investigator judges ineligible for other reasons

Minimum Eligible Age

20 Years

Maximum Eligible Age

49 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes